GO
| HSI1 | 24,498.95 | -18.81 | 236.41B |
| HSCEI1 | 8,853.10 | -8.29 | 74.68B |
| Back Zoom + Zoom - Block Traded | |
|
2025-07-16 11:03:01 Nomura has released a research report predicting a rebound in growth for WUXI BIO (02269.HK) in 1H25, with revenue/ net profit expected to increase by 13.8%/ 24.7% YoY, mainly due to a lower base in 1H24. It is likely that a similar trend will continue in 2HFY25. In addition, Nomura considered the strong growth of WUXI XDC (02268.HK), a subsidiary of WUXI BIO with a Buy rating, as a major growth driver for WUXI BIO. Excluding WUXI XDC, the broker estimated the sales growth to be around 6%. Nomura kept a Buy rating on WUXI BIO and slightly lowered its target price from HKD34.36 to HKD34.23, implying a 28% upside potential. ~ AAStocks Financial News Web Site: www.aastocks.com | |